Email ID
Password
Scrip   
Ception and Cephalon stumble on mixed Cinquil data
24 November 2009
Asher Mullard

A Phase IIb/III study of Ception Therapeutics' Cinquil (reslizumab) for the treatment of paediatric eosinophilic oesophagitis (EOE) has yielded mixed results, hitting only one of two co-primary endpoints. Cephalon, which holds an option to acquire privately-owned Ception, saw its share price fall...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36